(Hypertension. 1999;33:385-388.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From the Department of Physiology and Pharmacology and the Hypertension Center (T.N., M.F.C., P.L., C.M.F.), Wake Forest University Medical Center, Winston-Salem, NC; the Max Delbruck Center for Molecular Medicine (D.G.), Berlin, Germany; and the Department of Pharmacology and Toxicology (M.M.), Wright State University School of Medicine, Dayton, Ohio.
Correspondence to Mariana Morris, PhD, Department of Pharmacology and Toxicology, Box 927, Wright State University School of Medicine, Dayton, OH 45401. E-mail mmorris{at}wright.edu
| Abstract |
|---|
|
|
|---|
Key Words: genetics sodium brain vasopressin blood pressure rats, transgenic
| Introduction |
|---|
|
|
|---|
With regard to central nervous system (CNS) alterations in TG animals, brain levels of angiotensin peptides were increased, whereas angiotensin receptors were unchanged.2 8 The central infusion of Ang II in anesthetized female TG rats increased plasma vasopressin level but did not change blood pressure.15 However, a role for endogenous brain angiotensin receptors in the maintenance of salt-sensitive hypertension was suggested in studies in which male TG rats consumed 2% NaCl.8 Injection of an angiotensin AT1 receptor antisense oligonucleotide into the hypothalamic paraventricular nucleus reduced receptors and blood pressure but only in the salt-treated TG rats. These findings raise questions about the interactions between sodium and angiotensin in the control of blood pressure in the TG model. To explore the idea that endogenous changes in the brain RAS alters CNS responses, we evaluated the effect of cerebral ventricular injection of hypertonic saline and Ang II on blood pressure, heart rate (HR), and plasma vasopressin in conscious male TG rats.
| Methods |
|---|
|
|
|---|
Rats were anesthetized with ketamine/xylazine (71:6 mg/kg, IM). A 23-gauge stainless steel guide cannula was implanted into the left cerebral ventricle. The coordinates were as follows: 0.8 mm posterior to the bregma, 1.3 mm lateral to the midline, and 3.6 mm below the skull surface. The cannula was anchored to the skull with 2 stainless steel screws and dental cement. After a recovery period of 5 to 7 days, the right carotid artery was catheterized with PE-60 tubing for recording arterial blood pressure and collecting blood samples. The catheter was filled with heparinized saline (50 U/mL) and tunneled subcutaneously to exit at the back of the neck. The experiment was performed in conscious freely moving rats 2 days after the arterial catheterization.
Experimental Protocols
The arterial catheter was connected to a pressure
transducer (Microswitch), and arterial blood pressure was
measured with a Physiograph (model 5/6H, Gilson Medical Electronics).
After a 1-hour stabilization period, hypertonic saline (HS, 1 mol/L
NaCl, 5 µL) was injected
intracerebroventricularly over 60
seconds with a 33-gauge stainless steel injector, which extended 1
mm below the tip of the guide cannula. One and one-half hours after the
HS injection, Ang II (100 ng, 5 µL) was injected
intracerebroventricularly in the same
manner. Arterial blood pressure and HR were recorded
for 20 minutes (5 minutes before injection and 15 minutes after
injection). Mean arterial pressure (MAP) was calculated as
diastolic pressure plus one third the pulse pressure.
Initial experiments were conducted to determine that the order of the
injection did not influence the pressor response (Ang II after HS or
vice versa). Blood samples (0.8 mL) were withdrawn 15 minutes before
and 15 minutes after each
intracerebroventricular injection.
Blood was replaced with an equal volume of isotonic saline.
Plasma samples were extracted with acetone precipitation and petroleum ether extraction. Vasopressin was measured in the plasma extracts by a sensitive and specific radioimmunoassay.
Data Analysis
Data are expressed as mean±SEM. Statistical evaluation was
performed by ANOVA for repeated measures followed by Newman-Keuls
post-hoc test or unpaired t test. A significance level of
P<0.05 was used for all analyses.
| Results |
|---|
|
|
|---|
|
|
|
Effects of Intracerebral Injection of HS or Ang II
on Plasma Vasopressin
Baseline plasma vasopressin levels were not significantly
different between the groups (Figure 3
).
TG rats showed an increased vasopressin response to Ang II, 14 versus
28 pg/mL (control versus TG rats, respectively; Figure 3A
).
Central HS produced an increase in plasma vasopressin in both groups
with no significant difference in the responses (Figure 3B
).
|
| Discussion |
|---|
|
|
|---|
The Ren-2 TG rat is a model of fulminating hypertension produced by the insertion of the mouse Ren-2 gene into the rat genome.1 The transgene and its protein products are expressed in a variety of tissues, including the adrenal, testes, kidney, arteries, and brain and in other tissues.1 3 22 Our research has focused on the study of salt sensitivity in the TG rat, exploring the idea that activation of the RAS sensitizes the system to the effects of salt consumption. Indeed, drinking 2% NaCl caused a significant increase in blood pressure in TG rats , but not in control animals.7 This effect occurred rapidly within hours of ingestion and continued for the duration of the exposure. The blood pressure rise was associated with increased sympathetic and vasopressin drive.7 10 CNS angiotensin receptors appeared to be involved because blood pressure was reduced by central treatment with an AT1 receptor antisense.8 The present study supports the idea of CNS alterations in the TG animal with increased pressor responses noted for both angiotensin and osmotic stimuli. The results contrast with an earlier report by our group that showed a complete lack of angiotensin-induced pressor responses in the TG rats.15 However, there are differences between the protocols, notably the use of (1) halothane-anesthetized animals, (2) female rats, and (3) a different method and dose for angiotensin administration. For studies of the cardiovascular system, the conscious preparation is always preferable because anesthetics alter basal blood pressure and drug responses. With regard to the sex of the rats, there is evidence that the pressor response to central Ang II was diminished by estrogen.23 Finally, it should be noted that, although basal plasma vasopressin levels were high in the anesthetized animals, angiotensin increased vasopressin secretion, indicating that a segment of the receptor-mediated event was still present.
The primary mechanisms by which these stimuli alter blood pressure are sympathetic activation, baroreflex inhibition, and vasopressin release.5 17 The contribution of each component has been studied with the use of combinations of pharmacological antagonists. Here, we show a correlation between vasopressin secretion and blood pressure, especially for central angiotensin stimulation. However, this does not provide causal evidence. The antagonist to the vasopressin V1 pressor receptor did not alter the salt-induced increase in blood pressure in TG rats.10 Likewise, intravenous administration of HS caused a greater pressor response in TG rats, whereas the increase in plasma vasopressin was similar to that observed in control animals.11 Similarly, central osmotic stimulation caused an enhanced pressor, but not vasopressin, response. It is unlikely that the increase in peripheral vasopressin provides the total explanation for the pressor responses; rather, it is likely to be a combination of effector systems.
The pathways by which vasopressin release is stimulated by angiotensin and hypertonic saline involve interactions with osmotic and angiotensin receptors in the circumventricular regions in the forebrain with relays to the magnocellular neurons and the posterior pituitary. As mentioned previously, there is significant interaction between these systems as seen with the use of pharmacological blockade, lesions, and antisense treatment.19 20 21 24 25 Intracerebral Ang II and HS produced significant increases in plasma vasopressin in control and TG rats. The angiotensin response was significantly higher in the TG rats, whereas there was a tendency for an exaggerated response after HS (11.5 versus 19 pg/mL vasopressin, control versus TG rats). The experimental design may have contributed to this difference because Ang II was administered after hypertonic saline, perhaps acting to sensitize the animals to the second stimulus.
In conclusion, a genetic model in which there is continuing overexpression of the RAS provides evidence for a role of this system in the peptidergic and osmotic modulation of blood pressure and hormone secretion. The data provide further evidence for the important interrelationship between sodium and angiotensin in volume and pressure control.
| Acknowledgments |
|---|
Received September 17, 1998; first decision October 14, 1998; accepted October 30, 1998.
| References |
|---|
|
|
|---|
2. Senanayake P, Moriguchi A, Kumagai H, Ganten D, Ferrario CM, Brosnihan KB. Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides. 1994;15:919926.[Medline] [Order article via Infotrieve]
3.
Bader M, Zhao Y, Sander M, Lee MA, Bachmann J, Bohm M,
Djavidani B, Peters J, Mullins JJ, Ganten D. Role of tissue renin in
the pathophysiology of hypertension in TGR(mREN2)27 rats.
Hypertension. 1992;19:681686.
4.
Yang RH, Jin H, Chen SJ, Wyss JM, Oparil S. Blocking
hypothalamic AT1 receptors lowers blood pressure in salt-sensitive
rats. Hypertension. 1992;20:755762.
5. Phillips MI. Functions of angiotensin in the central nervous system. Annu Rev Physiol. 1987;49:413435.[Medline] [Order article via Infotrieve]
6. Buggy J, Hoffman WE, Phillips MI, Fisher AE, Johnson AK. Osmosensitivity of rat third ventricle and interactions with angiotensin. Am J Physiol. 1979;236:R75R82.
7.
Callahan MF, Li P, Ferrario CM, Ganten D, Morris M.
Salt sensitive hypertension in (mRen-2)27 transgenic rats.
Hypertension. 1996;27:573577.
8.
Li P, Morris M, Diz DI, Ferrario CM, Ganten D,
Callahan MF. Role of paraventricular
angiotensin AT1 receptors in salt-sensitive hypertension in
mRen-2 transgenic rats. Am J Physiol. 1996;270:R1178R1181.
9. Morris M, Li P, Ferrario CM, Ganten D, Callahan MF. Increased responsiveness of vasopressin mRNA to salt loading in mREN-2 transgenic rats. FASEB J. 1997;11:A218. Abstract.
10. Li P, Morris M, Ferrario CM, Barrett C, Ganten D, Callahan MF. Cardiovascular, endocrine and body fluid/electrolyte responses to salt loading in mRen-2 transgenic rats. Am J Physiol. 1998;275:H1130H1137.
11. Nishioka T, Morris M, Li P, Ganten D, Ferrario CM, Callahan MF. Depressor role of angiotensin AT2 receptors in the (mRen-2)27 transgenic rat. Am J Hypertens. 1998;11:357362.[Medline] [Order article via Infotrieve]
12. Schneider K, Gross V, Lippoldt A, Luft F. Exaggerated natriuresis in transgenic (mRen2)27 rats. J Hypertens. 1997;15:10411048.[Medline] [Order article via Infotrieve]
13. Brosnihan BK, Li P, Ganten D, Ferrario CM. Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilation balance of RAS. Am J Physiol. 1997;273:R1908R1915.
14.
Noll G, Lang MG, Tschudi MR, Ganten D, Luscher TF.
Endothelial vasoconstrictor prostanoids modulate
contractions to acetylcholine and ANG II in Ren-2 rats. Am J
Physiol. 1997;272:H493H500.
15.
Moriguchi A, Ferrario CM, Brosnihan KB, Ganten D,
Morris M. Differential regulation of central vasopressin in transgenic
rats harboring the mouse Ren-2 gene. Am J Physiol. 1994;267:R786R791.
16. Hohle S, Spitznagel H, Rascher W, Culman J, Unger T. Angiotensin AT1 receptor-mediated vasopressin release and drinking are potentiated by an AT2 receptor antagonist. Eur J Pharmacol. 1995;275:277282.[Medline] [Order article via Infotrieve]
17. Reid IA, Schwartz J, Ben L, Maselli J, Keil LC. Interactions between vasopressin and the renin-angiotensin system. Prog Brain Res.. 1983;60:475491.[Medline] [Order article via Infotrieve]
18. Bruner CA, Weaver JM, Fink GD. Sodium-dependent hypertension produced by chronic central angiotensin II infusion. Am J Physiol. 1985;249:H321H327.
19.
Sladek CD, Blair ML, Ramsay DJ. Further studies on the
role of angiotensin in the osmotic control of vasopressin
release by the organ-cultured rat hypothalamo-neurohypophyseal system.
Endocrinology. 1982;111:599607.
20. Hogarty DC, Speakman EA, Puig V, Phillips MI. The role of angiotensin AT1 and A2 receptors in the pressor, drinking and vasopressin responses to central angiotensin. Brain Res. 1992;586:289294.[Medline] [Order article via Infotrieve]
21. Hogarty DC, Tran DN, Phillips MI. Involvement of angiotensin receptor subtypes in osmotically induced release of vasopressin. Brain Res. 1994;637:126132.[Medline] [Order article via Infotrieve]
22.
Hilgers KF, Peters J, Veelken R, Sommer M, Rupprecht G,
Ganten D, Luft FC, Mann JF. Increased vascular angiotensin
formation in female rats harboring the mouse Ren-2 gene.
Hypertension. 1992;19:687691.
23. Jonklaas J, Buggy J. Angiotensin-estrogen interaction in female brain reduces drinking and pressor responses. Am J Physiol. 1984;247:R167R172.
24. Johnson AK. The periventricular anteroventral third ventricle (AV3V): its relationship with the subfornical organ and neural systems involved in maintaining body fluid homeostasis. Brain Res Bull. 1985;15:595601.[Medline] [Order article via Infotrieve]
25. Meng H, Wielbo D, Gyurko R, Phillips MI. Antisense oligonucleotide to AT1 receptor mRNA inhibits central angiotensin induced thirst and vasopressin. Regul Pept. 1994;54:543551.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
Y. Chen, H. Chen, and M. Morris Enhanced osmotic responsiveness in angiotensin AT1a receptor deficient mice: evidence for a role for AT1b receptors Exp Physiol, September 1, 2005; 90(5): 739 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. H. Zucker Brain Angiotensin II: New Insights Into Its Role in Sympathetic Regulation Circ. Res., March 22, 2002; 90(5): 503 - 505. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |